M
Marc Carrier
Researcher at Ottawa Hospital Research Institute
Publications - 396
Citations - 17092
Marc Carrier is an academic researcher from Ottawa Hospital Research Institute. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 58, co-authored 325 publications receiving 12428 citations. Previous affiliations of Marc Carrier include Ottawa Hospital & University of Ottawa.
Papers
More filters
Journal ArticleDOI
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli,Mahesh V. Madhavan,David Jiménez,Taylor Chuich,Isaac Dreyfus,Elissa Driggin,Caroline Der Nigoghossian,Walter Ageno,Mohammad Madjid,Yutao Guo,Liang V. Tang,Yu Hu,Jay Giri,Mary Cushman,Isabelle Quéré,Evangelos Dimakakos,C. Michael Gibson,C. Michael Gibson,Giuseppe Lippi,Emmanuel J. Favaloro,Jawed Fareed,Joseph A. Caprini,Alfonso Tafur,John R. Burton,Dominic P. Francese,Elizabeth Y. Wang,Anna Falanga,Claire McLintock,Beverley J. Hunt,Alex C. Spyropoulos,Geoffrey D. Barnes,John W. Eikelboom,John W. Eikelboom,Ido Weinberg,Sam Schulman,Marc Carrier,Gregory Piazza,Gregory Piazza,Joshua A. Beckman,P. Gabriel Steg,Gregg W. Stone,Stephan Rosenkranz,Samuel Z. Goldhaber,Samuel Z. Goldhaber,Sahil A. Parikh,Manuel Monreal,Harlan M. Krumholz,Stavros Konstantinides,Jeffrey I. Weitz,Gregory Y.H. Lip,Gregory Y.H. Lip +50 more
TL;DR: The current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexistingThrombotic disease who develop CO VID-19 are reviewed.
Journal ArticleDOI
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob,Nick van Es,Peter Verhamme,Marc Carrier,Marcello Di Nisio,David A. Garcia,Michael A. Grosso,Ajay K. Kakkar,Michael J. Kovacs,Michele Mercuri,Guy Meyer,Annelise Segers,Minggao Shi,Tzu-Fei Wang,Erik Yeo,George Zhang,Jeffrey I. Zwicker,Jeffrey I. Weitz,Harry R. Büller +18 more
TL;DR: Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration.
Journal ArticleDOI
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier,Karim Abou-Nassar,Ranjeeta Mallick,Vicky Tagalakis,Sudeep Shivakumar,Ariah Schattner,Philip Kuruvilla,Danny Hill,Silvana Spadafora,Katerine Marquis,Mateya Trinkaus,Anna Tomiak,Agnes Y.Y. Lee,Peter L. Gross,Alejandro Lazo-Langner,Robert El-Maraghi,Glenwood D. Goss,Grégoire Le Gal,David J. Stewart,Tim Ramsay,Marc A. Rodger,Debra Witham,Philip S. Wells,Avert Investigators +23 more
TL;DR: Apixaban therapy resulted in a significantly lower rate of venous thromboembolism than did placebo among intermediate‐to‐high‐risk ambulatory patients with cancer who were starting chemotherapy.
Journal ArticleDOI
Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report.
Lisa K. Moores,Tobias Tritschler,Tobias Tritschler,Shari B. Brosnahan,Marc Carrier,Jacob F. Collen,Jacob F. Collen,Kevin C. Doerschug,Aaron B. Holley,Aaron B. Holley,David Jiménez,Grégoire Le Gal,Parth Rali,Philip S. Wells +13 more
TL;DR: The evidence on the optimal strategies to prevent, diagnose, and treat venous thromboembolism in patients with COVID-19 is sparse, but rapidly evolving.
Journal ArticleDOI
Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism
TL;DR: The case-fatality rate of recurrent VTE decreases after completion of the initial period of anticoagulation and major bleeding events are similar during theInitial period of VTE treatment, suggesting that clinicians have a surrogate measure of mortality to balance the risks and benefits of antICOagulant therapy in patients with VTE.